论文部分内容阅读
目的:观察运用骨痨愈康丸联合来氟米特(LEF)治疗类风湿关节炎(RA)的临床疗效及相关实验室检查指标的变化情况。方法:将80例患者随机分为对照组和治疗组各40例,对照组单用来氟米特治疗。治疗组在此基础上加用骨痨愈康丸。治疗3月后评价2组临床疗效,并观察其炎症指标:血沉(ESR)、C-反应蛋白(CRP)、类风湿因子(RF)及免疫指标免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、免疫球蛋白G(IgG)、补体C3、补体C4等实验室指标的变化。结果:2组临床疗效比较,总有效率治疗组92.31%,对照组84.21%,差异有统计学意义(P<0.05)。治疗后,2组炎症指标ESR、CRP、RF分别与治疗前比较,差异均有统计学意义(P<0.05,P<0.01);治疗后,炎症指标ESR、CRP、RF治疗组治疗前后差值分别与对照组比较,差异均有统计学意义(P<0.05)。治疗后,2组免疫指标IgG、C3、C4,治疗组IgM等分别与治疗前比较,差异均有统计学意义(P<0.05,P<0.01);对照组IgA、IgM,治疗组IgA分别与治疗前比较,差异均无统计学意义(P>0.05);治疗后,治疗组IgA、IgM、C3、C4治疗前后差值分别与对照组比较,差异均有统计学意义(P<0.05)。结论:骨痨愈康丸联合来氟米特治疗类风湿关节炎,临床疗效良好,无明显不良反应。
OBJECTIVE: To observe the clinical efficacy and relevant laboratory tests of GuZuo YuKang Pill combined with leflunomide (LEF) in the treatment of rheumatoid arthritis (RA). Methods: Eighty patients were randomly divided into control group and treatment group, 40 cases in each group. The control group was treated with leflunomide alone. On the basis of the treatment group, Gujian Yu Kang Wan was added. After 3 months of treatment, the clinical efficacy of the two groups were evaluated and their inflammatory indexes such as ESR, CRP, RF, immune index IgA and immunoglobulin M (IgM), immunoglobulin G (IgG), complement C3, complement C4 and other laboratory indicators. Results: Compared with the two groups, the total effective rate was 92.31% in the treatment group and 84.21% in the control group, the difference was statistically significant (P <0.05). After treatment, the ESR, CRP and RF of the two groups of inflammation were significantly different from those before treatment (P <0.05, P <0.01); after treatment, the difference of ESR, CRP and RF in the two groups before and after treatment Compared with the control group, the differences were statistically significant (P <0.05). After treatment, IgA, IgM and IgM in the two groups were significantly different from those before treatment (P <0.05, P <0.01); IgA, IgM in the control group, Before treatment, the difference was not statistically significant (P> 0.05). After treatment, the difference between before and after treatment of IgA, IgM, C3 and C4 in the treatment group was statistically significant (P <0.05) compared with the control group. Conclusion: Guzhuyukang pill combined with leflunomide in the treatment of rheumatoid arthritis, clinical efficacy is good, no obvious adverse reactions.